The annual cost of providing semaglutide through the US’s Medicare health insurance programme to patients with cardiovascular disease (CVD) could range from $34bn to $145bn (£25.7bn to £110bn; €30.5bn to €130bn), research has shown. The research paper, published in the Annals of Internal...
www.bmj.com
"The annual cost of providing semaglutide (
i.e., Ozempic) through the US’s Medicare health insurance programme to patients with cardiovascular disease (CVD) could range from $34bn to $145bn . . . , research has shown."